supplementary material – Page 37 – Communicable Diseases Research

Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine

Research Article

Published on 2022-01-112022-10-28
Journal: Arthritis Research & Therapy [Category] COVID-19, SARS,

[키워드] adverse event anti-SARS-CoV-2 connective tissue Control control group controls COVID-19 disease dose evaluated event example female Fever first dose Follow-up Frequency healthy control immunization immunosuppressants incidence rate Inflammatory arthritis inhibitor injection investigated joint Local Logistic regression analysis low frequency males median median age Mild MOST mRNA vaccine Musculoskeletal occurred Occurrence Pain Patient patients pauci-symptomatic performed psoriatic arthritis reactogenicity remained reported Result Rheumatic musculoskeletal disease rheumatoid arthritis SARS-CoV-2 SARS-CoV-2 vaccination second dose subject supplementary material Symptom therapy Treatment vaccination Vaccine vaccine administration was recorded women
[DOI] 10.1186/s13075-021-02674-w PMC 바로가기 [Article Type] Research Article

SARS-CoV-2 Spike protein is not pro-inflammatory in human primary macrophages: endotoxin contamination and lack of protein glycosylation as possible confounders

Original Article

Published on 2022-01-112022-10-31
Journal: Cell Biology and Toxicology [Category] COVID-19, SARS,

Reliability of televisits for patients with mild relapsing–remitting multiple sclerosis in the COVID-19 era

Covid-19

Published on 2022-01-112022-10-30
Journal: Neurological Sciences [Category] Coronavirus, COVID19(2023년), SARS,

Assessment of COVID-19 vaccines acceptance in the Lebanese population: a national cross-sectional study

Research

Published on 2022-01-112022-10-29
Journal: Journal of Pharmaceutical Policy and Practice [Category] COVID-19,

Impact of the lockdown on acute stroke treatments during the first surge of the COVID-19 outbreak in the Netherlands

Research

Published on 2022-01-112022-10-27
Journal: BMC Neurology [Category] Coronavirus, SARS,

Prevalence of SARS-CoV-2 IgG antibodies among dental teams in Germany

독일 치과팀의 SARS-CoV-2 IgG 항체 유병률

Original Article

Published on 2022-01-112022-09-10
Journal: Clinical Oral Investigations [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술,

[키워드] adjusted analyzed applied association Blood blood sample clinical condition coronavirus demographic data dentist dentists detect Dry Epidemiology examined except for General population Germany IgG antibodies IgG antibody increased risk indicated infection control Laboratory Logistic material measure mixed-effects model mixed-effects models objective Occupational dentistry pandemic participant participants with SARS-CoV-2 Patient patients PCR test positive positive SARS-CoV-2 PCR positive SARS-CoV-2 PCR test Protective provided questionnaire Questionnaires Regulation reported Result risk risk factor SARS-CoV-2 SARS-CoV-2 IgG antibodies SARS-CoV-2 IgG antibody SARS-COV-2 infection SARS-CoV-2 transmission self-reported information significantly subject supplementary material variable were used Working conditions
[DOI] 10.1007/s00784-021-04363-z PMC 바로가기 [Article Type] Original Article

Systematic identification of ACE2 expression modulators reveals cardiomyopathy as a risk factor for mortality in COVID-19 patients

ACE2 발현 조절제의 체계적인 식별은 심근병증을 COVID-19 환자의 사망 위험 인자로 밝혀줍니다

Research

Published on 2022-01-102022-09-11
Journal: Genome Biology [Category] 유전자 메커니즘,

[키워드] ACE2 ACE2 expression Analysis angiotensin angiotensin-converting enzyme 2 Cardiomyopathy cardiovascular conditions categories characterized Comprehensive condition COVID-19 illness COVID-19 patient COVID-19 patients Critical dataset datasets develop disease drug drug treatment drug treatments drugs Electronic health record Electronic health records enzyme expression Genetic healthy heart HNF1A human tissue identify increased mortality Infection itraconazole joint Mortality overexpression Pathogenesis pathogenesis of COVID-19 Patient perturbations RAD140 receptor Result reveal risk risk factor Risk factors RNA-Seq SARS-CoV-2 SARS-COV-2 infection Seven severe COVID-19 illness supplementary material Transmission upregulation variance while
[DOI] 10.1186/s13059-021-02589-4 PMC 바로가기 [Article Type] Research

Oral cavity infection by the SARS-CoV-2: emphasizing the essence of masking and peptide therapeutics

Correspondence

Published on 2022-01-102022-11-01
Journal: The Egyptian Journal of Medical Human Genetics [Category] COVID-19,

Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology

가용성 CD24를 사용한 치료는 COVID-19 관련 전신 면역병리를 약화시킵니다

Clinical Trial

Published on 2022-01-102022-09-12
Journal: Journal of Hematology & Oncology [Category] 임상, 진단,

[키워드] acute respiratory syndrome coronavirus Analysis anti-inflammatory agent anti-inflammatory agents Anti-viral Antibody Response approach attenuate binding blunt cause CD24 CD24Fc CD4 CD56 CD8 cellular compartments chemokine chemokines Clinical characteristics Clinical efficacy coronavirus 2 coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 severity cytokine Cytokine score Cytokines damage damage-associated molecular pattern Damage-associated molecular patterns demonstrated downstream enrolled epithelial cells Extracellular flow cytometry heat shock proteins homeostasis homology Immune homeostasis immunopathology Immunophenotyping induce infected individuals Inflammatory response Lung epithelial cells Natural killer cells Pathogenesis pathway Patient patients with COVID-19 performed Peripheral blood peripheral blood samples phosphatase placebo group pro-inflammatory cytokine Protein Randomized Release respiratory Result return SARS-CoV-2 SARS-CoV-2-infected individuals severe acute respiratory syndrome coronavirus 2 severe COVID-19 severity shown Siglec10 significantly Soluble CD24 supplementary material systemic cytokine response systemic inflammation T cell T cells therapeutic therapeutic efficacy Treatment Trial with COVID-19
[DOI] 10.1186/s13045-021-01222-y PMC 바로가기 [Article Type] Clinical Trial

Plitidepsin as a successful rescue treatment for prolonged viral SARS-CoV-2 replication in a patient with previous anti-CD20 monoclonal antibody-mediated B cell depletion and chronic lymphocytic leukemia

이전에 항-CD20 단일클론 항체 매개 B 세포 고갈 및 만성 림프구성 백혈병이 있는 환자에서 장기간 바이러스 SARS-CoV-2 복제에 대한 성공적인 구조 치료제로서의 플리티뎁신

Case Reports

Published on 2022-01-102022-09-10
Journal: Journal of Hematology & Oncology [Category] SARS, 바이오마커, 진단,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 affected anti-CD20 Anti-CD20 monoclonal antibody Antiviral antiviral drug antiviral therapies antiviral therapy B cell CD19 CD20 chronic lymphocytic leukemia compassionate use coronavirus coronavirus disease Course COVID-19 COVID-19 pneumonia deficiency develop hematological Hematological malignancies Host immune Immune deficiencies Immunosuppressed Infection leukemia Lymphocytic leukemia male monoclonal monoclonal antibodies Patient Plitidepsin Pneumonia Population Prolonged viral replication resolved respiratory SARS-CoV-2 SARS-CoV-2 patient SARS-CoV-2 patients SARS-CoV-2 replication Severe COVID-19 pneumonia supplementary material Support toxicities treated Treatment treatment with anti-CD20 undetectable Viral Viral load
[DOI] 10.1186/s13045-021-01220-0 PMC 바로가기 [Article Type] Case Reports